Researchers identify genetic regulators of glycosylation in cancer, suggesting new treatment targets.
In this study, Wisnovsky and colleagues¹ investigate the genetic determinants underlying cancer-associated glycome remodeling. Using genome-wide CRISPR-based approaches, they identified regulators of cell surface glycosylation. Specifically, genetic networks are discovered that upregulate cancer-related ligands of the sialic acid-binding immunomodulatory Siglecs.
No takes yet. Share an insight, caveat, or question.
Decloquement et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: